Page 86 - 《中国药房》2025年19期

消银胶囊联合司库奇尤单抗治疗中重度斑块状银屑病的临床观察 Δ

＊
甘 泉 ，王贝贝，苏蓓蓓，王利霞（新乡市中心医院皮肤科，河南 新乡 453000）
#
中图分类号 R969.4；R758.63 文献标志码 A 文章编号 1001-0408（2025）19-2428-05
DOI 10.6039/j.issn.1001-0408.2025.19.12

摘 要 目的 评估消银胶囊联合司库奇尤单抗治疗中重度斑块状银屑病的临床疗效及安全性。方法 回顾性纳入2021年1月至
2024 年 6 月在新乡市中心医院皮肤科接受治疗的 105 例中重度斑块状银屑病患者，根据治疗方案分为常规组（n＝32）、单抗组
（n＝45）和联合组（n＝28）。常规组患者采用卡泊三醇软膏+丙酸氟替卡松乳膏+阿维A胶囊的常规治疗方案；单抗组患者在常规
组基础上加用司库奇尤单抗注射液；联合组患者在单抗组基础上联合口服消银胶囊。所有患者接受至少12周的治疗。比较3组
患者治疗前后的银屑病面积和严重程度指数（PASI）评分、PASI 评分改善率、皮肤病生活质量指数（DLQI）评分、医生整体评估
（PGA）评分、患者整体评估（PtGA）评分及治疗期间的不良反应发生情况。结果 治疗前，3组患者上述各项评分的差异均无统计
学意义（P＞0.05）。治疗后，3组患者上述各项评分均较治疗前显著降低（P＜0.05）；联合组患者的总PASI评分及红斑、鳞屑、受累
体表面积评分，总 DLQI 评分及症状感受、日常活动、社交评分，PGA 和 PtGA 评分均显著低于其他 2 组（P＜0.05），且 PASI 50（即
PASI评分较基线下降≥50%的患者比例，以此类推）、PASI 75、PASI 90均显著高于其他2组（P＜0.05）；单抗组患者的总PASI评分
及红斑、受累体表面积评分均显著低于常规组（P＜0.05），PASI 75 显著高于常规组（P＜0.05）。3 组患者的总不良反应发生率比
较，差异无统计学意义（P＝0.637）。结论 消银胶囊联合司库奇尤单抗可显著改善中重度斑块状银屑病患者的皮损及生活质量，
短期内具有良好的耐受性，且未明显增加严重不良反应的发生风险。
关键词 消银胶囊；中重度斑块型银屑病；司库奇尤单抗；临床疗效；生活质量；皮损

Clinical observation of Xiaoyin capsules combined with secukinumab in the treatment of moderate to
severe plaque psoriasis
GAN Quan，WANG Beibei，SU Beibei，WANG Lixia（Dept. of Dermatology， Xinxiang Central Hospital， Henan
Xinxiang 453000， China）

ABSTRACT OBJECTIVE To evaluate the clinical efficacy and safety of Xiaoyin capsules combined with secukinumab in the
treatment of moderate to severe plaque psoriasis. METHODS A retrospective study was conducted on 105 patients with moderate to
severe plaque psoriasis who received treatment in the Dept. of Dermatology of Xinxiang Central Hospital from January 2021 to June
2024. According to the treatment plan， they were divided into conventional group（n＝32）， monoclonal antibody group（n＝45），
and combination group（n＝28）. The conventional group was given Calcipotriol ointment+Fluticasone propionate cream+Acitretin
capsules； the monoclonal antibody group was treated with secukinumab injection in addition to the treatment of the conventional
group； the combination group received oral administration of Xiaoyin capsules in addition to the treatment of the monoclonal
antibody group. All patients received at least 12 weeks of treatment. The psoriasis area and severity index（PASI） score， PASI
improvement rate， dermatology life quality index（DLQI） score， physician’s global assessment（PGA） score， patient’s global
assessment（PtGA） score before and after treatment， and the incidence of adverse reactions during treatment were compared among
the three groups. RESULTS Before treatment， there was no statistically significant difference in the above scores among the three
groups（P＞0.05）. After treatment， the scores of all three groups of patients significantly decreased compared to before treatment
（P＜0.05）； the total PASI score and erythema， scales， affected body surface area score， the total DLQI score and symptom
perception， daily activity， social score， the PGA and PtGA scores of the combination group were significantly lower than the other
two groups（P＜0.05）； PASI 50（the proportion of patients whose PASI score decreased by ≥50% from baseline， and so on）， PASI
75， and PASI 90 were significantly higher than the other two groups（P＜0.05）； the total PASI score， erythema， and affected body
surface area score of patients in the monoclonal antibody group were significantly lower than the conventional group（P＜0.05）， and
PASI 75 was significantly higher than the conventional group（P＜0.05）. There was no statistically significant difference in the total
incidence of adverse reactions among the 3 groups（P＝0.637）. CONCLUSIONS The combination of Xiaoyin capsules and
secukinumab can significantly improve the skin lesions and quality of life in patients with moderate to severe plaque psoriasis， with
good tolerability in the short term and no significant increase
Δ 基金项目 河南省医学科技攻关计划项目（No.LHGJ20240853）
＊第一作者 主治医师，硕士。研究方向：银屑病、皮肤肿瘤的治 in the risk of serious adverse reactions.
疗。E-mail：ganquancc@163.com KEYWORDS Xiaoyin capsules； moderate to severe plaque
# 通信作者 主任医师。研究方向：银屑病、皮肤肿瘤的治疗。 psoriasis； secukinumab； clinical efficacy； quality of life； skin
E-mail：Wanglx5566@126.com lesion

· 2428 · China Pharmacy 2025 Vol. 36 No. 19 中国药房 2025年第36卷第19期